Endovascular Engineering, Inc.

Endovascular Engineering, Inc. is a US-based medical technology firm dedicated to developing advanced clot removal devices for venous thromboembolism, enhancing treatment options for pulmonary embolism management. Endovascular Engineering, Inc. focuses on creating innovative medical technologies aimed at clot removal.

The company is headquartered in Menlo Park, US. Mike Rosenthal leads the firm as CEO. The company has raised a total of USD 42. 00 mn in Series B funding, co-led by 415 CAPITAL and S3 Ventures, and received backing from other investors including Cordis Corporation and Panakes Partners.

This latest funding will advance the development of their Hēlo PE thrombectomy system while completing the ENGULF trial. The company has undertaken three deals since its inception, with the most recent deal occurring on February 18, 2025. Endovascular Engineering, Inc. specializes in the development of innovative clot removal technologies, specifically targeting venous thromboembolism.

Their flagship product, the Hēlo™ PE Thrombectomy System, is designed for the effective treatment of pulmonary embolism through a unique self-expanding design that allows for optimal clot engagement with a smaller catheter profile. This technology combines high-speed agitation with physician-controlled aspiration to facilitate the breakdown and removal of clots, providing significant advantages in navigating complex anatomies. The company’s solutions are aimed at healthcare providers, particularly interventional cardiologists and radiologists, who require advanced tools for managing vascular conditions. Currently, Endovascular Engineering is focused on markets in North America and Europe, where there is a growing demand for effective embolism treatment options.

Endovascular Engineering operates within a business-to-business framework, primarily engaging with hospitals and healthcare institutions that utilize their thrombectomy systems. The company structures its transactions around the sale of medical devices, particularly the Hēlo™ PE Thrombectomy System, which is currently for investigational use only and not commercially available. Revenue generation is anticipated through partnerships with healthcare providers, focusing on deployment trials and clinical studies. As the company advances its product through the regulatory process, they may also establish pricing plans that align with the needs of their clinical partners, which typically include upfront costs related to device acquisition and potential ongoing service agreements tied to training and support.

Endovascular Engineering, Inc. plans to utilize the recent Series B funding of USD 42. 00 mn to further the development of its Hēlo PE thrombectomy system and to complete the ENGULF trial, a critical step in their product's regulatory journey. The company is also considering expansion into new markets, particularly targeting European countries where there is an increasing demand for effective embolism treatment options by 2026.